Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

Sacco JC, Abouraya M, Motsinger-Reif A, Yale SH, McCarty CA, Trepanier LA.

Pharmacogenet Genomics. 2012 Oct;22(10):733-40. doi: 10.1097/FPC.0b013e328357a735.

2.

Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Funk-Keenan J, Sacco J, Wong YY, Rasmussen S, Motsinger-Reif A, Trepanier LA.

J Vet Intern Med. 2012 Sep-Oct;26(5):1126-33. doi: 10.1111/j.1939-1676.2012.00965.x. Epub 2012 Jul 21.

3.

Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women.

Blanke KL, Sacco JC, Millikan RC, Olshan AF, Luo J, Trepanier LA.

Cancer Causes Control. 2014 Nov;25(11):1513-21. doi: 10.1007/s10552-014-0454-7. Epub 2014 Sep 16.

4.

Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.

Sacco JC, Trepanier LA.

Pharmacogenet Genomics. 2010 Jan;20(1):26-37. doi: 10.1097/FPC.0b013e3283343296.

5.

Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.

Rhoads K, Sacco JC, Drescher N, Wong A, Trepanier LA.

Toxicol Sci. 2011 Jun;121(2):245-56. doi: 10.1093/toxsci/kfr073. Epub 2011 Mar 29.

6.

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.

Wadelius M, Stjernberg E, Wiholm BE, Rane A.

Pharmacogenetics. 2000 Feb;10(1):35-41.

PMID:
10739170
7.

Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA.

J Clin Pharmacol. 2012 Feb;52(2):272-8. doi: 10.1177/0091270010393343. No abstract available.

8.

Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

Zielińska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M.

Pharm World Sci. 1998 Jun;20(3):123-30.

PMID:
9618736
9.

Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP, Rochani JT, Wikaningrum R, Miyashita R, Miyagawa T, Sofro AS, Tokunaga K.

J Hum Genet. 2008;53(3):201-9. Epub 2007 Dec 27.

PMID:
18160997
10.

Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics.

Kim JM, Park BL, Park SM, Lee SH, Kim MO, Jung S, Lee EH, Uh ST, Park JS, Choi JS, Kim YH, Kim MK, Choi IS, Cho SH, Choi BW, Park HS, Chang HS, Shin HD, Park CS.

Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.

PMID:
20602614
11.

Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, Velayati AA.

Eur J Clin Pharmacol. 2004 Sep;60(7):467-71.

PMID:
15316701
12.

N-acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy.

Westphal GA, Reich K, Schulz TG, Neumann C, Hallier E, Schnuch A.

Br J Dermatol. 2000 Jun;142(6):1121-7.

PMID:
10848734
13.

 NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.

Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, Li X, Tu D, Chen Y, Deng P, Ma Y, Chen D, Chen R, Zhan S.

Ann Hepatol. 2012 Sep-Oct;11(5):700-7.

14.

Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.

Gu J, Liang D, Wang Y, Lu C, Wu X.

Mutat Res. 2005 Mar 7;581(1-2):97-104. Epub 2004 Dec 16.

PMID:
15725609
15.

Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population.

Sekine A, Saito S, Iida A, Mitsunobu Y, Higuchi S, Harigae S, Nakamura Y.

J Hum Genet. 2001;46(6):314-9.

PMID:
11393533
16.

Arylamine N-acetyltransferase-2 genotypes in the Thai population.

Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B.

Br J Clin Pharmacol. 2003 Mar;55(3):278-81.

17.

Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.

Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK.

Pharmacogenetics. 2000 Nov;10(8):705-13.

PMID:
11186133
18.

Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity.

O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK.

J Clin Pharmacol. 2002 Jun;42(6):613-9.

PMID:
12043950
19.
20.

Genetic variation in CYB5R3 is associated with methemoglobin levels in preterm infants receiving nitric oxide therapy.

Fuller TD, Spracklen CN, Ryckman KK, Knake LA, Busch TD, Momany AM, Murray JC, Dagle JM.

Pediatr Res. 2015 Mar;77(3):472-6. doi: 10.1038/pr.2014.206. Epub 2014 Dec 18.

Supplemental Content

Support Center